Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-18
2005-01-18
Lacourciere, Karen A. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S002600, C536S024500, C435S006120
Reexamination Certificate
active
06844324
ABSTRACT:
A versatile modular peptide mediated intracellular delivery system is disclosed which may be particularly adapted to facilitate the delivery of therapeutic compounds which are large in size or complex in nature. The invention relates both to a modular peptide mediated intracellular delivery system and a method of delivering a compound into a cell using the system.
REFERENCES:
patent: 5714353 (1998-02-01), Pathak et al.
patent: 5877282 (1999-03-01), Nadler et al.
patent: 5929042 (1999-07-01), Troy et al.
patent: 5981273 (1999-11-01), Curiel et al.
patent: 6080724 (2000-06-01), Chassaing et al.
Schofield et al, British Med. Bull, vol. 51, No. 1, pp. 56-71, 1995.*
Crooke, S.T., Antisense Research and Application, Chapter 1, pp. 1-50, published by Springer-Verlag, 1998.*
Branch, A.D., Trends in Biochem. Sci. (TIBS), vol. 23, pp. 45-50, 1998.*
Crystal, R.G., Science, vol. 270, pp. 404-410, 1995.*
Verma et al, Nature, vol. 389, pp. 239-242, 1997.*
Friedmannj, T., Scientific American, Jun. vol., pp. 96-101, 1997.*
Schwartz and Zhang Peptide mediated cellular delivery. Current Opinion in Molecular Therapeutics. Feb. 2000 2(2) p 162 167.*
Adam, S., “Transport pathways of macromolecules between the nucleus and the cytoplasm,”Current Opinion in Cell Biology, 11:402-406(1999).
Albini, A., et al., “Antiogenic properties of human immunodeficiency virus type 1 Tat protein,” Proc. Natl. Acad. Sci. USA, 92:4838-4842 (1995).
Aldrian-Herrada, G., et al., “A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons,”Nucl. Acid Res., 26:4910-4916 (1998).
Anderson W.F., “Human gene therapy,”Nature, 392(Suppl 6679):25-30 (1998).
Aramburu, J., et al., “Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A,”Science, 285:2129-2133 (1999).
Avrameas, A., et al., “Efficient gene delivery by a peptide derived from a monoclonal anti-DNA antibody,”Bioconjug. Chem. 10:87-93 (1999).
Avrameas, A., et al., “Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules,”Proc. Natl. Acad. Sci. USA, 95:5601-5606(1998).
Bab, I., et al., “Biosynthesis of Osteogenic Growth Peptide via Alternative Translational Initiation at AUG85of Histone H4 mRNA,”The Journal of Biological Chemistry, 274(20):14474-14481(1999).
Barbier, B., and Brack, A., “Conformation-Controlled Hydrolysis of Polyribonucleotides by Sequential Basic Polypeptides,”J. Am. Chem. Soc., 114:3511-3515(1992).
Baxevanis, A., and Landsman, D., “Histone Sequence Database: new histone fold family members,”Nucleic Acids Research, 26(1):372-375(1998).
Beasley, J., and Hecht, M., “Protein Design: The Choice of de Nova Sequences,”The Journal of Biological Chemistry, 272(4):2031-2034(1997).
Bralet, M.P., et al., “Cell Lineage Study in the Liver Using Retroviral Mediated Gene Transfer,”American Journal of Pathology, 144(5):896-904(1994).
Chakrabartty, A., et al., “Helix capping propensities in peptides parallel those in proteins,”Proc. Natl. Acad. Sci. USA, 90:11332-11336(1993).
Chalfie, M., et al., “Green Fluorescent Protein as a Marker for Gene Expression,”Science, 263:802-805(1994).
Chatelin, L., et al., “Transcription factor Hoxa-5 is taken up by cells in culture and conveyed to their nuclei,”Mechanisms of Development, 55:111-117(1996).
Chen, J., et al., “A novel gene delivery system using EGF receptor-mediated endocytosis,”FEBS Letters, 338:167-169(1994).
Cotten, M., et al., “High-efficiency receptor-mediated delivery of small and large (48 kilobase gene constructs using the endosome-disruption activity of defective or chemically inactivated adenovirus particles,”Proc. Natl. Acad. Sci. USA, 89:6094-6098(1992).
Crystal, R. G., “Transfer of Genes to Humans: Early Lessons and Obstacles to Success,”Science, 270:404-410(1995).
Damante, G., et al., “A molecular code dictates sequence-specific DNA recognition by homeodomains,”The EMBO Journal, 15(18):4992-5000(1996).
Darquet, A-M., et al., “Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer,”Gene Therapy, 6:209-218(1999).
de Nooy, A. E. J., et al., “Highly selective nitroxyl radical-mediated oxidation of primary alcohol groups in water-soluble glucans,”Carbohydrate Research, 269:89-98(1995).
Derer, W., et al., “Direct protein transfer to terminally differentiated muscle cells,”J. Mol. Med.77:609-613 (1999).
Derossi, D., et al., “Trojan peptides: The penetratin system for intracellular delivery,”Trends Cell Biol. 8:84-87 (1998).
Derossi, D., et al., “The Third Helix of the Antennapedia Homeodomain Translocates through Biological Membranes,”The Journal of Biological Chemistry, 269(14):10444-10450(1994).
Derossi, D., et al., “Cell Internalization of the Third Helix of the Antennapedia Homeodomain Is Receptor-independent,”The Journal of Biological Chemistry, 271(30):18188-18193(1996).
Diebold, S.S., et al., “Efficient Gene Delivery into Human Dendritic Cells by Adenovirus Polyethylenimine and Mannose Polyethylenimine Transfection,”Human Gene Therapy, 10:775-786(1999).
DiGabriele, A.D., et al., “Structure of a heparin-linked biologically active dimer of fibroblast growth factor,”Nature, 393:812-817(1998).
Dilber, M.S., et al., “Intracellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22,”Gene Therapy, 6:12-21(1999).
Dorn, A., et al., “Homeodomain Proteins in Development and Therapy,”Pharmac. Ther., 61:155-183(1994).
Douglas, J. T., and Curiel, D.T., “Adenoviruses as Vectors for Gene Therapy,”Science&Medicine, pp. 44-53 (Mar./Apr. 1997).
Dove, A., and Marshall, A., “Proteins break on through to the other side,”Nature Biotechnology, 17:942(1999).
Duguid, J.G., et al., “A Physicochemical Approach for Predicting the Effectiveness of Peptide-Based Gene Delivery Systems for Use in Plasmid-Based Gene Therapy,”Biophysical Journal, 74:2802-2814(1998).
Durell, S. R., et al., “What studies of fusion peptides tell us about viral envelope glycoprotein-mediated membrane fusion (Review),”Molecular Membrane Biology, 14:97-112(1997).
Efthymiadis, A., et al., “The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties,”J. Biol. Chem., 273:1623-1628 (1998).
Elliot, G. and O'Hare, P.,“Intercellular trafficking and protein delivery by a herpesvirus structural protein,”Cell, 88:223-233 (1997).
Elliot, G. and O'Hare, P., “Intercellular trafficking of VP22-GFP fusion proteins,”Gene Therapy, 6:149-151 (1999).
Ennist, D.L., “Gene therapy for lung disease,”Trends Pharmacol. Sci. 20:260-266 (1999).
Erbacher, P., et al., “Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway,”Gene Therapy, 6:138-145 (1999).
Fawell, S., et al., “Tat-mediated delivery of heterologous proteins into cells,”Proc. Natl. Acad. Sci. USA, 91:664-648 (1994).
Fasbender, A., et al., “Complexes of Adenovirus with Polycationic Polymers and Cationic Lipids Increase the Efficiency of Gene Transfer in Vitro and In Viro,”The Journal of Biological Chemistry, 272(10):6479-6489(1997).
Ferrari, S., et al., “Polyethylenimine shows properties of interest for cystic fibrosis gene therapy,”Biochim. Biophys. Acta, 1447:219-225 (1999).
Ferry, N., and Heard, J.M., “Liver-Directed Gene Transfer Vectors,”Human Gene Therapy, 9:1975-1981(1998).
Feyzi, E., et al., “Characterization of Heparin
Schwartz John J.
Zhang Shuguang
Hamilton Brook Smith & Reynolds P.C.
Lacourciere Karen A.
Massachusetts Institute of Technology
LandOfFree
Modular peptide mediated intracellular delivery system and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modular peptide mediated intracellular delivery system and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modular peptide mediated intracellular delivery system and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3405939